Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review

Lisa Moris; Marcus G Cumberbatch; Thomas Van den Broeck; Giorgio Gandaglia; Nicola Fossati; Brian Kelly; Raj Pal; Erik Briers; Philip Cornford; Maria De Santis; Stefano Fanti; Silke Gillessen; Jeremy P Grummet; Ann M Henry; Thomas B L Lam; Michael Lardas; Matthew Liew; Malcolm D Mason; Muhammad Imran Omar; Olivier Rouvière; Ivo G Schoots; Derya Tilki; Roderick C N van den Bergh; Theodorus H van Der Kwast; Henk G van Der Poel; Peter-Paul M Willemse; Cathy Y Yuan; Badrinath Konety; Tanya Dorff; Suneil Jain; Nicolas Mottet; Thomas Wiegel

doi:10.1016/j.eururo.2020.01.033

Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review

Lisa Moris, Marcus G Cumberbatch, Thomas Van den Broeck, Giorgio Gandaglia, Nicola Fossati, Brian Kelly, Raj Pal, Erik Briers, Philip Cornford, Maria De Santis, Stefano Fanti, Silke Gillessen, Jeremy P Grummet, Ann M Henry, Thomas B L Lam, Michael Lardas, Matthew Liew, Malcolm D Mason, Muhammad Imran Omar, Olivier RouvièreIvo G Schoots, Derya Tilki, Roderick C N van den Bergh, Theodorus H van Der Kwast, Henk G van Der Poel, Peter-Paul M Willemse, Cathy Y Yuan, Badrinath Konety, Tanya Dorff, Suneil Jain, Nicolas Mottet, Thomas Wiegel

Research output: Contribution to journal › Review article › peer-review

Abstract

High-risk and locally advanced prostate cancer (PCa) patients are likely to undergo multimodality treatment. Patients should at all times be fully informed about all available options and the likelihood of a multimodal approach, including the potential side effects of both local and systemic treatment. For high-risk localized and locally advanced PCa, both radical prostatectomy as part as multimodal therapy and external beam radiotherapy (EBRT) + long-term androgen deprivation therapy (ADT) can be recommended as primary treatment. For high-risk localized PCa, EBRT + BT can also be offered despite a less favorable toxicity profile. In selected high-risk PCa patients, a shorter duration of ADT might be considered. Until the results of the SPCG15 trial are known, the optimal local treatment remains a matter of debate.

Original language	English
Pages (from-to)	614-627
Number of pages	14
Journal	European Urology
Volume	77
Issue number	5
DOIs	https://doi.org/10.1016/j.eururo.2020.01.033
Publication status	Published - May 2020

Keywords

Prostate cancer
Localized
Locally advanced
Primary therapy
Radical prostatectomy
External beam radiotherapy
Brachytherapy
Modality treatment
Systemic treatment
Systematic review

Access to Document

10.1016/j.eururo.2020.01.033

Cite this

Moris, L., Cumberbatch, M. G., Van den Broeck, T., Gandaglia, G., Fossati, N., Kelly, B., Pal, R., Briers, E., Cornford, P., De Santis, M., Fanti, S., Gillessen, S., Grummet, J. P., Henry, A. M., Lam, T. B. L., Lardas, M., Liew, M., Mason, M. D., Omar, M. I., ... Wiegel, T. (2020). Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. European Urology, 77(5), 614-627. https://doi.org/10.1016/j.eururo.2020.01.033

@article{22b2c14af60043f3ac9d407ce664a848,

title = "Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review",

abstract = "High-risk and locally advanced prostate cancer (PCa) patients are likely to undergo multimodality treatment. Patients should at all times be fully informed about all available options and the likelihood of a multimodal approach, including the potential side effects of both local and systemic treatment. For high-risk localized and locally advanced PCa, both radical prostatectomy as part as multimodal therapy and external beam radiotherapy (EBRT) + long-term androgen deprivation therapy (ADT) can be recommended as primary treatment. For high-risk localized PCa, EBRT + BT can also be offered despite a less favorable toxicity profile. In selected high-risk PCa patients, a shorter duration of ADT might be considered. Until the results of the SPCG15 trial are known, the optimal local treatment remains a matter of debate.",

keywords = "Prostate cancer, Localized, Locally advanced, Primary therapy, Radical prostatectomy, External beam radiotherapy, Brachytherapy, Modality treatment, Systemic treatment, Systematic review",

author = "Lisa Moris and Cumberbatch, {Marcus G} and {Van den Broeck}, Thomas and Giorgio Gandaglia and Nicola Fossati and Brian Kelly and Raj Pal and Erik Briers and Philip Cornford and {De Santis}, Maria and Stefano Fanti and Silke Gillessen and Grummet, {Jeremy P} and Henry, {Ann M} and Lam, {Thomas B L} and Michael Lardas and Matthew Liew and Mason, {Malcolm D} and Omar, {Muhammad Imran} and Olivier Rouvi{\`e}re and Schoots, {Ivo G} and Derya Tilki and {van den Bergh}, {Roderick C N} and {van Der Kwast}, {Theodorus H} and {van Der Poel}, {Henk G} and Willemse, {Peter-Paul M} and Yuan, {Cathy Y} and Badrinath Konety and Tanya Dorff and Suneil Jain and Nicolas Mottet and Thomas Wiegel",

year = "2020",

month = may,

doi = "10.1016/j.eururo.2020.01.033",

language = "English",

volume = "77",

pages = "614--627",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier",

number = "5",

}

Moris, L, Cumberbatch, MG, Van den Broeck, T, Gandaglia, G, Fossati, N, Kelly, B, Pal, R, Briers, E, Cornford, P, De Santis, M, Fanti, S, Gillessen, S, Grummet, JP, Henry, AM, Lam, TBL, Lardas, M, Liew, M, Mason, MD, Omar, MI, Rouvière, O, Schoots, IG, Tilki, D, van den Bergh, RCN, van Der Kwast, TH, van Der Poel, HG, Willemse, P-PM, Yuan, CY, Konety, B, Dorff, T, Jain, S, Mottet, N & Wiegel, T 2020, 'Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review', European Urology, vol. 77, no. 5, pp. 614-627. https://doi.org/10.1016/j.eururo.2020.01.033

TY - JOUR

T1 - Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer

T2 - An International Multidisciplinary Systematic Review

AU - Moris, Lisa

AU - Cumberbatch, Marcus G

AU - Van den Broeck, Thomas

AU - Gandaglia, Giorgio

AU - Fossati, Nicola

AU - Kelly, Brian

AU - Pal, Raj

AU - Briers, Erik

AU - Cornford, Philip

AU - De Santis, Maria

AU - Fanti, Stefano

AU - Gillessen, Silke

AU - Grummet, Jeremy P

AU - Henry, Ann M

AU - Lam, Thomas B L

AU - Lardas, Michael

AU - Liew, Matthew

AU - Mason, Malcolm D

AU - Omar, Muhammad Imran

AU - Rouvière, Olivier

AU - Schoots, Ivo G

AU - Tilki, Derya

AU - van den Bergh, Roderick C N

AU - van Der Kwast, Theodorus H

AU - van Der Poel, Henk G

AU - Willemse, Peter-Paul M

AU - Yuan, Cathy Y

AU - Konety, Badrinath

AU - Dorff, Tanya

AU - Jain, Suneil

AU - Mottet, Nicolas

AU - Wiegel, Thomas

PY - 2020/5

Y1 - 2020/5

N2 - High-risk and locally advanced prostate cancer (PCa) patients are likely to undergo multimodality treatment. Patients should at all times be fully informed about all available options and the likelihood of a multimodal approach, including the potential side effects of both local and systemic treatment. For high-risk localized and locally advanced PCa, both radical prostatectomy as part as multimodal therapy and external beam radiotherapy (EBRT) + long-term androgen deprivation therapy (ADT) can be recommended as primary treatment. For high-risk localized PCa, EBRT + BT can also be offered despite a less favorable toxicity profile. In selected high-risk PCa patients, a shorter duration of ADT might be considered. Until the results of the SPCG15 trial are known, the optimal local treatment remains a matter of debate.

AB - High-risk and locally advanced prostate cancer (PCa) patients are likely to undergo multimodality treatment. Patients should at all times be fully informed about all available options and the likelihood of a multimodal approach, including the potential side effects of both local and systemic treatment. For high-risk localized and locally advanced PCa, both radical prostatectomy as part as multimodal therapy and external beam radiotherapy (EBRT) + long-term androgen deprivation therapy (ADT) can be recommended as primary treatment. For high-risk localized PCa, EBRT + BT can also be offered despite a less favorable toxicity profile. In selected high-risk PCa patients, a shorter duration of ADT might be considered. Until the results of the SPCG15 trial are known, the optimal local treatment remains a matter of debate.

KW - Prostate cancer

KW - Localized

KW - Locally advanced

KW - Primary therapy

KW - Radical prostatectomy

KW - External beam radiotherapy

KW - Brachytherapy

KW - Modality treatment

KW - Systemic treatment

KW - Systematic review

UR - http://www.scopus.com/inward/record.url?scp=85081015872&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2020.01.033

DO - 10.1016/j.eururo.2020.01.033

M3 - Review article

C2 - 32146018

SN - 0302-2838

VL - 77

SP - 614

EP - 627

JO - European Urology

JF - European Urology

IS - 5

ER -

Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this